Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances

Biohaven Ltd.

2023-Q3 EPS reported -$3.86

Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).
Cash, cash equivalents and securities $495M as of Oct 5, 2023, including $242M net from public offering of 11.76M shares at $22.
BHV-1300 IgG degrader showed >90% IgG reduction in non-human primates; IND submission on track for 2023.
BHV-7000 Phase 1 EEG study confirmed CNS target engagement; Phase 3 focal epilepsy trial to start in 2023.
Completed enrollment in Phase 3 study of taldefgrobep alfa in SMA; troriluzole MAA under EMA review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.